TW254939B - - Google Patents

Info

Publication number
TW254939B
TW254939B TW081104300A TW81104300A TW254939B TW 254939 B TW254939 B TW 254939B TW 081104300 A TW081104300 A TW 081104300A TW 81104300 A TW81104300 A TW 81104300A TW 254939 B TW254939 B TW 254939B
Authority
TW
Taiwan
Application number
TW081104300A
Other languages
Chinese (zh)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10696001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW254939(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of TW254939B publication Critical patent/TW254939B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Secondary Cells (AREA)
  • Medicinal Preparation (AREA)
TW081104300A 1991-06-03 1992-06-02 TW254939B (en:Method)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919111902A GB9111902D0 (en) 1991-06-03 1991-06-03 Chemical compounds

Publications (1)

Publication Number Publication Date
TW254939B true TW254939B (en:Method) 1995-08-21

Family

ID=10696001

Family Applications (1)

Application Number Title Priority Date Filing Date
TW081104300A TW254939B (en:Method) 1991-06-03 1992-06-02

Country Status (30)

Country Link
US (1) US5905082A (en:Method)
EP (2) EP1099700A1 (en:Method)
JP (1) JP2851480B2 (en:Method)
KR (1) KR100244008B1 (en:Method)
AP (1) AP300A (en:Method)
AT (1) ATE212630T1 (en:Method)
AU (2) AU1881092A (en:Method)
BG (1) BG60914B1 (en:Method)
CA (2) CA2070230C (en:Method)
CZ (1) CZ284513B6 (en:Method)
DE (1) DE69232387T2 (en:Method)
DK (1) DK0517145T3 (en:Method)
ES (1) ES2171158T3 (en:Method)
GB (1) GB9111902D0 (en:Method)
GE (1) GEP19991834B (en:Method)
IE (2) IE921780A1 (en:Method)
IL (1) IL102073A (en:Method)
IS (2) IS1867B (en:Method)
MX (1) MX9202619A (en:Method)
NO (1) NO301713B1 (en:Method)
NZ (1) NZ242981A (en:Method)
OA (1) OA09913A (en:Method)
PT (1) PT517145E (en:Method)
RU (1) RU2102393C1 (en:Method)
SG (1) SG52455A1 (en:Method)
SK (1) SK281249B6 (en:Method)
TW (1) TW254939B (en:Method)
UA (1) UA41265C2 (en:Method)
WO (1) WO1992021676A1 (en:Method)
ZA (1) ZA924007B (en:Method)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4581979A (en) * 1983-07-01 1986-04-15 Automotive Products Plc Shipping and installation restraining clip for master cylinder input member
US5914331A (en) 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5827727A (en) 1990-02-01 1998-10-27 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
US6177435B1 (en) 1992-05-13 2001-01-23 Glaxo Wellcome Inc. Therapeutic combinations
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5703058A (en) 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
ATE346651T1 (de) 1995-06-07 2006-12-15 Univ Emory Nucleoside mit anti-hepatitis b virus wirksamkeit
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
WO1997049411A1 (en) 1996-06-25 1997-12-31 Glaxo Group Limited Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
PT1574512E (pt) * 2001-03-01 2008-03-05 Abbott Lab Formas polimórficas e outras formas cristalinas de cis-ftc
US6600044B2 (en) 2001-06-18 2003-07-29 Brantford Chemicals Inc. Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers
WO2003027106A1 (en) * 2001-09-25 2003-04-03 Cadila Healthcar Limited Process for the preparation of crystalline polymorph ii of lamivudine
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
AU2003291457A1 (en) * 2002-11-08 2004-06-03 Glaxo Group Limited Pharmaceutical antiviral compositions
EA015145B1 (ru) 2003-01-14 2011-06-30 Джилид Сайэнс, Инк. Фармацевтическая композиция и пероральная фармацевтическая дозированная форма (варианты), проявляющие активность в отношении вич-инфекций, лечебный набор и таблетка и способ лечения или предотвращения симптомов или эффектов вич-инфекции
ES2318575T3 (es) * 2004-11-10 2009-05-01 Novartis Vaccines And Diagnostics, Inc. Interferon beta desamidado.
US20060242012A1 (en) * 2005-04-22 2006-10-26 Sumit Agarwal Determining or scoring properties to solicit to join ad network using advertiser or aggregated advertiser interest
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
US8158607B2 (en) 2006-04-18 2012-04-17 Lupin Limited Crystalline form of lamivudine
AR068374A1 (es) * 2007-09-06 2009-11-11 Combino Pharm Sl Nuevas composiciones farmaceuticas del complejo lamivudina beta - ciclodextrina
US20100190982A1 (en) * 2007-09-17 2010-07-29 Janardhana Rao Vascuri Process for the preparation of lamivudine form i
BRPI0820222A2 (pt) * 2007-11-29 2015-06-16 Ranbaxy Lab Ltd Forma i cristalina estável de lamivudina e processo de preparação
EP2227478A1 (en) * 2007-11-29 2010-09-15 Ranbaxy Laboratories Limited Process and intermediates for the preparation of substituted 1, 3-oxathiolanes, especially lamivudine
WO2009069011A1 (en) * 2007-11-29 2009-06-04 Ranbaxy Laboratories Limited Process for the preparation of substituted 1,3-oxathiolanes
WO2009127996A1 (en) * 2008-04-17 2009-10-22 Ranbaxy Laboratories Limited Novel crystalline form of lamivudine
EP2318398A4 (en) * 2008-09-01 2011-12-07 Hetero Research Foundation PROCESS FOR PREPARING A POLYMORPHIC FORM OF LAMIVUDIN
EP2350065A1 (en) * 2008-11-12 2011-08-03 Lupin Ltd. A novel polymorph of emtricitabine and a process for preparing of the same
CN101531656B (zh) * 2009-03-24 2010-12-08 福建广生堂药业有限公司 拉米夫定晶型及其制备方法
CN101993439B (zh) * 2009-03-24 2013-04-24 福建广生堂药业股份有限公司 拉米夫定晶型及其制备方法
US8481554B2 (en) * 2009-05-27 2013-07-09 Hetero Research Foundation Solid oral dosage forms of lamivudine
WO2011007367A1 (en) 2009-07-15 2011-01-20 Lupin Limited An improved process for preparation of efavirenz
EP2488516B1 (en) 2009-10-14 2015-04-01 Mylan Laboratories Limited Process for the preparation of lamivudine and novel salts in the manufacture thereof
UA105556C2 (uk) 2010-01-27 2014-05-26 Віів Гелскер Компані Комбінація сполук, що містить інгібітори віл інтегрази з іншими терапевтичними агентами
WO2011095987A1 (en) * 2010-02-03 2011-08-11 Matrix Laboratories Ltd. Novel process for the preparation of cis-nucleoside derivative
AU2011215878A1 (en) 2010-02-12 2012-08-09 Merck Sharp & Dohme Corp. Preparation of lamivudine Form I
CN104203275A (zh) 2010-06-09 2014-12-10 疫苗技术股份有限公司 用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫
WO2013021290A1 (en) 2011-08-05 2013-02-14 Lupin Limited A stereoselective process for preparation of 1,3-oxathiolane nucleosides
WO2013168066A1 (en) 2012-05-05 2013-11-14 Lupin Limited An improved process for the manufacture of lamivudine form i.
CN114099454B (zh) * 2020-08-31 2023-06-27 长春海悦药业股份有限公司 一种拉米夫定片及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
JPH04358486A (ja) * 1991-06-04 1992-12-11 Toshiba Corp 高能率符号化信号処理装置

Also Published As

Publication number Publication date
WO1992021676A1 (en) 1992-12-10
NO301713B1 (no) 1997-12-01
IS4268A (is) 1995-02-27
AU1736192A (en) 1993-03-11
IE921780A1 (en) 1992-12-16
IS3873A (is) 1992-12-04
DE69232387D1 (de) 2002-03-14
CA2070230C (en) 2004-08-03
DE69232387T2 (de) 2002-09-26
IS1867B (is) 2003-05-02
GB9111902D0 (en) 1991-07-24
JPH06211848A (ja) 1994-08-02
NZ242981A (en) 1994-04-27
SK281249B6 (sk) 2001-01-18
RU2102393C1 (ru) 1998-01-20
AU656379B2 (en) 1995-02-02
DK0517145T3 (da) 2002-05-06
OA09913A (en) 1994-09-15
MX9202619A (es) 1992-12-01
EP0517145A1 (en) 1992-12-09
ES2171158T3 (es) 2002-09-01
AU1881092A (en) 1993-01-08
CZ284513B6 (cs) 1998-12-16
NO922182L (no) 1992-12-04
KR100244008B1 (ko) 2000-03-02
SG52455A1 (en) 1998-09-28
IE20020782A1 (en) 2003-04-02
CZ261293A3 (en) 1994-04-13
PT517145E (pt) 2002-07-31
SK125793A3 (en) 1994-11-09
GEP19991834B (en) 1999-11-05
UA41265C2 (uk) 2001-09-17
CA2311988A1 (en) 1992-12-04
BG98254A (bg) 1994-07-29
IL102073A0 (en) 1993-01-14
ZA924007B (en) 1993-04-28
IL102073A (en) 1996-05-14
US5905082A (en) 1999-05-18
EP0517145B1 (en) 2002-01-30
CA2070230A1 (en) 1992-12-04
EP1099700A1 (en) 2001-05-16
AP300A (en) 1994-01-20
KR930000511A (ko) 1993-01-15
NO922182D0 (no) 1992-06-02
HK1009599A1 (en) 1999-06-04
BG60914B1 (bg) 1996-06-28
AP9200395A0 (en) 1992-07-31
ATE212630T1 (de) 2002-02-15
CA2311988C (en) 2005-11-15
JP2851480B2 (ja) 1999-01-27

Similar Documents

Publication Publication Date Title
TW250494B (en:Method)
EP0545581A3 (en:Method)
DE4290950T1 (en:Method)
DE4290919T1 (en:Method)
DE4290412T1 (en:Method)
DK0518777T3 (en:Method)
DE4290402T1 (en:Method)
DE4290741T1 (en:Method)
DE4291109T1 (en:Method)
DK0569364T3 (en:Method)
TW206996B (en:Method)
DE4290056T1 (en:Method)
DK0545490T3 (en:Method)
TW223052B (en:Method)
ATA37391A (en:Method)
ECSM91543U (en:Method)
ECSM91563U (en:Method)
ECSM91562U (en:Method)
ECSM91525U (en:Method)
ECSM91530U (en:Method)
ECSDI910041S (en:Method)
AU8463091A (en:Method)
EP0529755A3 (en:Method)
AU7714891A (en:Method)
AU8454191A (en:Method)

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent